Actively Recruiting
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Led by Peking University People's Hospital · Updated on 2024-12-03
50
Participants Needed
1
Research Sites
50 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.
CONDITIONS
Official Title
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Histopathological confirmation of classic high-grade osteosarcoma
- Newly diagnosed stage II or III osteosarcoma based on Enneking staging
- Planned to receive neoadjuvant chemotherapy
- Measurable disease on CT scan by RECIST 1.1 criteria
- No prior systemic antitumor therapy
- ECOG performance status of 0 or 1
- Adequate organ function
- Agreement to use effective contraception during the study and for 6 months after for females of childbearing potential, males, and their partners
You will not qualify if you...
- History of other types of malignancies
- Allergy to any study agent
- History of psychotropic substance abuse, alcohol, or drug use
- Considered inappropriate for study participation by researchers for any reason
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here